Tigatuzumab

• CAT Number: I042437
• CAS Number: 918127-53-4
• Molecular Weight: 144.6 (kDa)
• Purity: ≥95%

Tigatuzumab (Cat No.: I042437) is a humanized monoclonal antibody targeting death receptor 5 (DR5), a member of the TNF receptor superfamily involved in apoptosis signaling. By binding to DR5, Tigatuzumab activates the extrinsic apoptotic pathway, selectively inducing cell death in tumor cells while sparing normal tissues. It has shown promise in preclinical and clinical studies for treating various cancers, including colorectal, pancreatic, and non-small cell lung cancer. Tigatuzumab is used in combination therapies to enhance anticancer efficacy through immune-mediated and apoptotic mechanisms.

Reference

[1]. Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 2020 Nov 1;492:174-184.
[Content Brief]